Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet.
Two PRP programmes are present on the IMPACT platform:
| Concentration vs. whole blood1 | Yield | |||
|---|---|---|---|---|
| Cell Types | Platelets | Leukocytes | Erythrocytes | Platelets |
| rPRP | 2-3 x | <0,9 x | <0,15 x | 95% |
| wPRP | 2-3 x | <0,2 x | <0,01 x | 92% |
Two APC programmes are present on the IMPACT platform:
| Concentration vs. whole blood1 | Yield | |||
|---|---|---|---|---|
| Cell Types | Platelets | Leukocytes | Erythrocytes | Platelets |
| rACP (1 ml) | >6 x | 6 x | <0,9 x | 86% |
| wACP (1 ml) | >4 x | <0,5 x | <0,03 x | 74% |
Oversupply of IL-1Ra versus IL-1ß
IL-1ß : IL-1Ra > 1 : 10
No significant increase of TNFa
TNFa (Whole blood) = TNFa(ACS
L-1Ra > 500pg/ml
Growth factors and cytokines like for example IL-10, IGF, PDGF
(1) Serum concentrations: TU Munich, Chair of Medical Technology
